Surmodics to Webcast Fourth Quarter and Fiscal Year 2016 Earnings Conference Call on November 16
- Nasdaq ends at record high as Big Tech roars back
- Sanderson Farms (SAFM) Explores Sale - Report
- Bitcoin (BTC) Cracks $30,000 to Hit 6-Month Low, Here Are Next Targets Lower
- Dollar lower as Powell reaffirms pledge to not raise rates too quickly
- Splunk (SPLK) Lands $1 Billion From Silver Lake, Announces Buyback One Day After Activist Rumors Surface
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Webcast is Live at 7:30 a.m. (CT)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter and fiscal year 2016 conference call on Wednesday, November 16, at 7:30 a.m. CT (8:30 a.m. ET). The Company will issue an earnings news release earlier that morning.
Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and information systems and chief financial officer, will recap the fourth quarter and fiscal year 2016 financial results and accomplishments as well as provide 2017 guidance. To access the webcast, go to the investor relations portion of the Company’s website at www.surmodics.com the day of the conference call and click on the webcast icon.
An audio replay will be available beginning at 10:30 a.m. CT on Wednesday, November 16, until 10:30 a.m. CT on Wednesday, November 23, and can be accessed by dialing 888-203-1112 and entering conference call ID passcode 8067923. In addition, the conference call audio and transcript will be archived on the Company’s website following the call.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) tests and microarrays. Following two recent acquisitions of Creagh Medical and NorMedix, the Company is executing a key growth strategy for its medical device business by expanding to offer total intravascular product solutions to its medical device customers. The combination of proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities, enables Surmodics to significantly increase the value it offers with highly differentiated intravascular solutions designed and engineered to meet the most demanding requirements. With this focus on offering total product solutions, Surmodics’ mission remains to improve the detection and treatment of disease by using its technology to provide solutions to difficult medical device and diagnostic challenges. Surmodics is headquartered in Eden Prairie, Minnesota. For more information about the company, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.
Andy LaFrence, 952-500-7000
Source: Surmodics, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Focus Financial Partners Inc. (FOCS) Launches Secondary Offering of 7.4M Shares
- Torchlight Energy Resources (TRCH) updated its prospectus to sell another $150 million in common stock through Roth Capital
- AptarGroup (ATR) Announces Exclusive Negotiations Regarding a Potential Acquisition of Voluntis to Expand in Digital Therapeutics
Create E-mail Alert Related CategoriesPress Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!